Managing the complexity of change: Introducing a therapeutic innovation for SMA in two Italian Regions

Journal title MECOSAN
Author/s Elisabetta Trinchero, Monica Otto
Publishing Year 2024 Issue 2023/128
Language Italian Pages 14 P. 9-22 File size 0 KB
DOI 10.3280/mesa2023-128oa18586
DOI is like a bar code for intellectual property: to have more infomation click here

View article Download Open Access article

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

The paper presents the implementation of the therapeutic management path of patients being treated with a drug for Spinal Muscular Atrophy (SMA) in two regional Italian contexts, focusing on the role of multi-professional networks.Through interviews with professionals involved in therapeutic management at the “Città della Salute e della Scienza” University Hospital in Turin, the “Città di Torino”Local Health Authority, and the Marche Region Health Service (ASUR), the work highlights the complexity of introducing therapeutic innovations for rare diseases. The context, pharmaceutical management policies, drug access, and challenges in providing care for SMA patients are examined in detail. It describes how multi-professional involvement and organization among hospital centers have facilitated the access to treatment while identifying future training challenges and new medication management.

Keywords: ; Rare diseases; Spinal Muscular Atrophy; Medication management; Multi-disciplinary team

  1. Chabanon A., Seferian A.M., Daron A., Péréon Y., Cances C., Vuillerot C., et al. (2018). Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS One, 13, e0201004. DOI: 10.1371/journal.pone.0201004
  2. D’Amico A., Mercuri E., Tiziano F.D., Bertini E. (2011). Spinal muscular atrophy. Orphanet J Rare Dis., Nov 2, 6, 71. DOI: 10.1186/1750-172-6-71
  3. Eisenhardt K.M., & Graebner M.E. (2007). Theory Building From Cases: Opportunities And Challenges. Academy of Management Journal, 50(1): 25-32. DOI: 10.5465/amj.2007.24160888
  4. Eisenhardt K. M., & Bourgeois L. J. (1988). Politics of strategic decision making in high-velocity environments: Toward a midrange theory. Academy of Management Journal, 31(4): 737-770. DOI: 10.2307/256337
  5. Farrar M.A., Park S.B., Vucic S., Carey K.A., Turner B.J., Gillingwater T.H. et al. (2017). Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol, 81: 355-68. DOI: 10.1002/ana.24864
  6. Gioia D.A., Corley K.G., & Hamilton A.L. (2013). Seeking qualitative rigor in inductive research: notes on the Gioia methodology. Organisational Research Methods, 16(1): 15-31.
  7. Kolb S.J., Kissel J.T. (2015). Spinal Muscular Atrophy. Neurol Clin, 33: 831-46. DOI: 10.1016/j.ncl.2015.07.004
  8. Mercuri E., Finkel R.S., Muntoni F., Wirth B., Montes J., Main M. et al. (2018). Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders, 28: 103-15. DOI: 10.1016/j.nmd.2017.11.005
  9. Miniño A.M., Xu J., Kochanek K.D. (2010). Deaths: preliminary data for 2008. Natl Vital Stat Rep., Dec, 59(2): 1-52.
  10. Morando V., Ferrara L., Tozzi V.D. (2017). Position paper sulla presa in carico delle malattie rare e ultrarare in Italia: generalizzazioni a partire dal caso paradigmatico delle malattie da accumulo lisosomiale. Mecosan, 102: 7-31.
  11. Ogino S., Leonard D.G., Rennert H., Ewens W.J., Wilson R.B. (2002). Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet., Jul 15, 110(4): 301-7. DOI: 10.1002/ajmg.10425
  12. Piano Integrato di Attività e Organizzazione 2022-2024 dell’ASUR Marche.
  13. Sugarman E.A., Nagan N., Zhu H., Akmaev V.R., Zhou Z., Rohlfs E.M., Flynn K., Hendrickson B.C., Scholl T., Sirko-Osadsa D.A., Allitto B.A. (2012). Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72,400 specimens. Eur J Hum Genet., Jan, 20(1): 27-32. DOI: 10.1038/ejhg.2011.134
  14. Tizzano E.F., Finkel R.S.. (2017). Spinal muscular atrophy: A changing phenotype beyond the clinical trials. Neuromuscular Disorders, 27: 883-9. DOI: 10.1016/j.nmd.2017.05.011
  15. Wang C.H., Finkel R.S., Bertini E.S., Schroth M., Simonds A., Wong B. et al. (2007). Consensus Statement for Standard of Care in Spinal Muscular Atrophy. J Child Neurol, 22: 1027-49. DOI: 10.1177/0883073807305788
  16. Yin R.K. (2013). Case Study Research Design and Methods, 3rd Ed. Los Angeles: Sage.

Elisabetta Trinchero, Monica Otto, Governare la complessità del cambiamento: l’introduzione di una innovazione terapeutica per la SMA in due realtà regionali italiane in "MECOSAN" 128/2023, pp 9-22, DOI: 10.3280/mesa2023-128oa18586